Business Context and Reporting Period
This Form 8-K Current Report was filed by Armata Pharmaceuticals, Inc. (ARMP) on April 27, 2026, regarding events occurring on April 24, 2026. The filing discloses the appointment of a new member to the Board of Directors and associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on corporate governance and director compensation.
- Director Retainer: $40,000 per year (cash).
- Equity Award: Option to purchase 51,280 shares of common stock.
- Exercise Price: Fair market value on the date of grant.
- Vesting Schedule: Equal installments over three years.
Material Changes
The primary material change is the expansion of the Board of Directors with the appointment of Dr. Daniel Gilmer, age 39, effective April 24, 2026. He will serve until the next annual meeting of shareholders. Committee assignments for Dr. Gilmer have not yet been determined.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of risks and contingencies. It notes that there are no family relationships between Dr. Gilmer and existing directors or officers, and no undisclosed arrangements influenced his selection.
Investor Verification Checklist
- Verify the fair market value of the stock on the grant date to determine the exercise price of the 51,280 options.
- Review the Company's 2016 Stock Incentive Plan (as amended) for specific terms governing the option award.
- Monitor future filings for Dr. Gilmer's specific committee assignments.
- Confirm the date of the next annual meeting of shareholders to determine the end of Dr. Gilmer's initial term.